Navigation Links
KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business
Date:6/10/2008

ST. LOUIS, June 10 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded products and generic/non-branded prescription pharmaceuticals, today reported that it has become aware of litigation filed by a smaller generic drug company, Lannett Company, Inc., challenging the patent rights associated with PrimaCare ONE(R), a prenatal vitamin product marketed by KV's Ther-Rx branded pharmaceutical business unit. KV has not yet been served in the lawsuit.

"We are reviewing the claims in this lawsuit and we will defend this and any other challenge to our patent rights vigorously," stated Marc S. Hermelin, KV's Chairman of the Board and Chief Executive Officer. "Our long-standing expertise in the development and marketing of both branded and generic/unbranded products positions us well to aggressively defend this type of lawsuit, which is not uncommon in our industry. In addition, we will continue to pursue various other strategies to meet the needs of patients in the therapeutic categories we serve with innovative and cost-effective products."

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim", "believe", "projects", "anticipates", "commit", "intend", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's litigation, anticipated SEC filings, strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward- looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, competitive, litigation, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts; (13) risks that the Company may not ultimately prevail in litigation, including challenges to our intellectual property rights by actual or potential competitors, including Lannett Company Inc.; (14) completion of the Company's financial statements for the first, second and third quarters of fiscal 2008 and for the full fiscal year ended March 31, 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; and (16) the risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission.

This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.


'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)...  BioElectronics Corporation (OTC Pink: BIEL), the maker ... it is responding to a notice of an ... Exchange Commission posted on the agency website.  ... Board of BioElectronics Corporation and the Edward and ... Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... has an active R&D program for the development of ... Group has a unique research and development center in ... Bio Control products. Stockton has a ... regulatory guidelines, and is active in more than 35 counties ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/5/2016)... ATCC, the premier global biological materials resource ... and life science researchers that are working to address ... CDC website . --> CDC ... a single-stranded RNA virus of the Flaviviridae family, genus ... Chikungunya Viruses. Zika virus is transmitted to humans primarily ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 25, 2016   Unisys Corporation (NYSE: UIS ) ... Kennedy (JFK) International Airport, New York City , ... imposters attempting to enter the United States ... pilot testing of the system at Dulles last ... at JFK during January 2016. --> pilot testing ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
Breaking Biology News(10 mins):